Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.
作者信息
FLETCHER A P, ALKJAERSIG N, SHERRY S
出版信息
J Clin Invest. 1962 Apr;41(4):896-916. doi: 10.1172/JCI104546.
Abstract
摘要
相似文献
1
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products.
J Clin Invest. 1962 Apr;41(4):896-916. doi: 10.1172/JCI104546.
2
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.
J Clin Invest. 1962 Apr;41(4):917-34. doi: 10.1172/JCI104547.
3
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy.
J Clin Invest. 1962 Apr;41(4):935-48. doi: 10.1172/JCI104548.
4
Fibrinogen and fibrin degradation products in hemolytic transfusion reactions.
Transfusion. 1970 Nov-Dec;10(6):317-21. doi: 10.1111/j.1537-2995.1970.tb00751.x.
5
[Fibrinolysis and fibrinolytic hemorrhagic diatheses].
J Med Lyon. 1952 Oct 5;33(786):869-81.
6
Fibrinogen Marburg a new genetic variant of fibrinogen.
Blut. 1977 Feb;34(2):107-18. doi: 10.1007/BF00999857.
7
CURRENT STATUS OF THROMBOLYTIC THERAPY.
Geriatrics. 1964 Sep;19:628-43.
8
[Fibrinolysis as a cause of hemorrhagic diathesis].
Ugeskr Laeger. 1956 Apr 26;118(15):403-8.
9
[Hypodysfibrinogenemia: fibrinogen giessen II (author's transl)].
Klin Wochenschr. 1975 Aug 15;53(16):781-2. doi: 10.1007/BF01614861.
10
[BLOOD COAGULATION DISORDERS DURING LABOR WITH SPECIAL REFERENCE TO FIBRINOLYSIS].
Geburtshilfe Frauenheilkd. 1965 Jan;25:46-55.
引用本文的文献
1
Thrombolytic Therapy.
Br Med J. 1963 Jun 8;1(5344):1492-4.
2
TO-DAY'S DRUGS. FIBRINOLYTIC ENZYMES AND FIBRINOLYTIC INHIBITORS.
Br Med J. 1965 Mar 13;1(5436):704-6.
3
HAEMORRHAGE AND FIBRINOLYSIS.
Proc R Soc Med. 1964 Jul;57(7):603-6. doi: 10.1177/003591576405700733.
4
ABNORMAL PLASMINOGEN-PLASMIN SYSTEM ACTIVITY (FIBRINOLYSIS) IN PATIENTS WITH HEPATIC CIRRHOSIS: ITS CAUSE AND CONSEQUENCES.
J Clin Invest. 1964 Apr;43(4):681-95. doi: 10.1172/JCI104953.
5
CURRENT APPRAISAL OF THROMBOLYTIC THERAPY. A CRITICAL REVIEW.
Calif Med. 1963 Nov;99(5):301-7.
6
CIRCULATING FIBRINOLYTIC ACTIVATOR AND HEMORRHAGIC DIATHESIS.
Ann Surg. 1963 Jul;158(1):117-25. doi: 10.1097/00000658-196307000-00021.
7
[Thromboelastographic studies on the blood clot structure in the Sanarelli-Shwartzman phenomenon].
Klin Wochenschr. 1963 Mar 1;41:216-9. doi: 10.1007/BF01487695.
8
Thrombolytic therapy.
Proc R Soc Med. 1963 May;56(5):414-8. doi: 10.1177/003591576305600536.
9
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. III. Demonstration of abnormal clot structure by electron microscopy.
J Clin Invest. 1962 Apr;41(4):935-48. doi: 10.1172/JCI104548.
10
Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.
J Clin Invest. 1962 Apr;41(4):917-34. doi: 10.1172/JCI104547.
本文引用的文献
1
Prothrombin and Fibrinolysin.
Science. 1946 Nov 15;104(2707):461-2. doi: 10.1126/science.104.2707.461.
2
Thrombin formation; effects of lysin (fibrinolysin, plasmin) on prothrombin, Ac-globulin and tissue thromboplastin.
J Clin Invest. 1949 Nov;28(6 Pt 2):1507-10. doi: 10.1172/JCI102216.
3
The protease and antiprotease of plasmas of patients with cancer and other diseases.
Cancer Res. 1949 Nov;9(11):665-8.
4
[Fatal hemorrhagic syndromes with total incoagulability and with fibrinolysis; in pulmonary exeresis].
Rev Hematol. 1952;7(1):30-47.
5
Studies on a proteolytic enzyme in human plasma. VII. A fatal hemorrhagic state associated with excessive plasma proteolytic activity in a patient undergoing surgery for carcinoma of the head of the pancreas.
J Clin Invest. 1952 May;31(5):521-8. doi: 10.1172/JCI102636.
6
Effects of ions and neutral molecules on fibrin clotting.
J Biol Chem. 1951 Aug;191(2):735-56.
7
Studies on afibrinogenemia. II. The defibrinating effect on dog blood of intravenous injection of thromboplastic material.
Bull Johns Hopkins Hosp. 1951 May;88(5):414-24.
8
A new method for the determination of fibrinogen in small samples of plasma.
J Lab Clin Med. 1951 Feb;37(2):316-20.
9
Chemical, clinical and immunological studies on the products of human plasma fractionation XL. Quantitative separation and determination of the protein components in small amounts of normal human plasma.
J Clin Invest. 1951 Jan;30(1):99-111. doi: 10.1172/JCI102423.
10
Etiology of fibrinopenia: fibrination defibrination.
Ann N Y Acad Sci. 1959 Jan 9;75:634-75. doi: 10.1111/j.1749-6632.1959.tb44581.x.
Zotero 插件